The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies.
Pablo BerlangaGaëlle PierronLudovic LacroixMathieu ChicardTiphaine Adam de BeaumaisAntonin MarchaisAnne C HarttrampfYasmine IddirAlicia LariveAroa Soriano FernandezImene HezamCecile ChevassusVirginie BernardSophie CotteretJean Yves ScoazecArnaud GauthierSamuel D AbbouNadege CorradiniAnne Isabelle BertozziIsabelle AertsEstelle ThebaudMichela CasanovaCormac OwensRaquel Hladun-AlvaroStefan MichielsOlivier DelattreGilles VassalGudrun SchleiermacherDidier FrappazPublished in: Cancer discovery (2022)
MAPPYACTS underlines the feasibility of molecular profiling at cancer recurrence in children on a multicenter, international level and demonstrates benefit for patients with selected key drivers. The use of cfDNA deserves validation in prospective studies. Our study highlights the need for innovative therapeutic proof-of-concept trials that address the underlying cancer complexity. This article is highlighted in the In This Issue feature, p. 1171.